Drug Profile

TransCon RBZ - Ascendis Pharma

Alternative Names: EYC-0305; TransCon-RBZ

Latest Information Update: 28 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ascendis Pharma
Class Eye disorder therapies; Immunoglobulin fragments
Mechanism of Action Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Wet age-related macular degeneration

Most Recent Events

19 May 2026 Phase-I/II clinical trials in Wet age-related macular degeneration in USA (Intravitreous) (NCT07587515)
18 May 2026 Eyconis plans a phase I/II (OVERTURE) trial for Wet age-related macular degeneration (Intravitreous, Injection) in the USA in May 2026 (NCT07587515)
12 Feb 2026 Ascendis Pharma plans clinical trials for Wet age-related macular degeneration in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com